Real Chemistry and WhizAI are teaming up to map the path patients take from diagnosis to treatment. By creating patient journey software, the collaborators aim to help clients market to identified audiences “in ways that are most authentic to the patient experience.”
Companies use journey mapping to uncover the process that patients go through to get care, complete a treatment plan and reach a desired outcome. The mapping can identify opportunities to improve the process to the benefit of both the patient and the drugmaker.
As Dan Fisher, practice leader for IPM.ai, part of Real Chemistry, noted, patient journey mapping “isn’t new.” Yet, Fisher and his collaborators think the combination of Real Chemistry’s analytics engine and WhizAI’s generative-AI-powered visualization platform has delivered an offering that stands out from the pack.
“This dynamic platform will allow users to ask questions about specific disease states and, through generative AI and analytics, have their questions answered with best-in-class data and insights, enabling better patient outcomes,” Fisher said in a statement. Bijal Karande, vice president, partnerships, WhizAI, added that the platform uses “generative AI to streamline the process for clients to access precise, context-based and real-time insights.”
IPM.ai, the business Fisher works at, is focused on using AI and real-world data to assess the market for drug candidates and improve the identification of patients, including people who have the targeted condition but are undiagnosed and misdiagnosed. Uncovering the diagnostic and treatment journey is part of the process.
Real Chemistry’s client list suggests the platform could end up being used by leading drugmakers. The agency, which generated revenues of $555 million last year, says it works with the top 30 pharma and biotech companies and has previously named AstraZeneca and Pfizer as clients.